Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The "Prefilled Syringe Fill Finish Manufacturing Market: Industry Trends and Global Forecasts - Distribution by Type of Therapeutic Area, Type of Syringe ...

Key market opportunities in the Prefilled Syringes Market include rapid growth driven by GLP-1 obesity therapeutics and rising self-injection demand, preference for COP over glass to mitigate ...

MGS says Auto-injector Reimagined drug-delivery device, which harnesses its design and moldmaking capabilities, can help ...

BioTechnique broadens capabilities with end‑to‑end fill‑finish, advanced lyophilization development, and integrated multi‑temperature 3PL support. YORK, PA, UNITED STATES, March 5, 2026 /EINPresswire.

CrossLink IGNITE Program -- Incentive initiative launched July 2025 and expanded, credited with accelerating ZYNRELEF ...

Kesimpta is a biologic drug, which means it’s made from parts of living organisms. It contains the active ingredient ofatumumab. Kesimpta belongs to a group of drugs called monoclonal antibodies. It ...

Alger Small Cap Focus Fund reviews Q4 2025 performance and the impact of the artificial intelligence capital cycle. Read the full analysis for more details.

Avonex is a prescription drug that treats relapsing forms of multiple sclerosis (MS) in adults, such as relapsing-remitting MS, active secondary progressive MS, and clinically isolated syndrome.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2025 Earnings Call Transcript February 26, 2026 Amphastar Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.73 EPS, ...

© 2026 American City Business Journals. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement ...